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In the year 500 before Christ, the Greek philosopher
Heraclitus said, “if one does not expect the unexpected,
one will not find it out, since the mind is not open to it,
and one will not search for it.” This is, in short, the pro-
blem I have with predicting what the future therapeutic
options for Pompe disease might be. Leaving out the
unthinkable, there are still plenty of options left, but
how realistic are they? Rather shortly after his discovery
of the lysosomes, in 1955, Prof Christian De Duve
hypothesized that lysosomal storage diseases could pos-
sibly be treated by enzyme therapy, the way we currently
practise. Nevertheless, the first successful attempt at
enzyme replacement therapy (ERT) in Gaucher disease,
by Dr Roscoe Brady and colleagues, was not published
until 1990. The trick they used to deliver human gluco-
cerebrosidase to Kupffer cells in the liver and to macro-
phages in bone marrow and spleen was to modify the
carbohydrates so the enzyme would be captured by the
mannose-receptor on these cells. At present, enzyme
replacement therapy is applied in Pompe disease, in
Fabry disease, and in the mucopolysaccharidoses MPS I,
II and VI. In all these latter diseases, the enzymes are
targeted to the mannose 6-phosphate receptor. In my
opinion ERT works best in Pompe disease, and its effect
could be further improved by starting treatment with
Myozyme or Lumizyme earlier and by using more than
the prescribed dose (20 mg/kg), if deemed clinically
necessary. Immunologic responses are contra-effective
and need to be minimized. Increasing the mannose 6-
phosphate content of rhGAA chemically, or by using an
alternative production platform, is expected to improve
the efficacy of ERT. Improving the binding of rhGAA to
the mannose 6-phosphate / IGF-II like receptor by pro-
duction of a fusion protein (GILT- technology) might
equally lead to greater efficacy. The co-application of
chaperones is seen as a further option. Meanwhile, gene
therapy is considered the solution to all problems. The
principle was demonstrated in 1971, but it was only
three days ago that the first gene therapy was approved
by regulatory authorities in the Western world. For the
treatment of Pompe disease, gene therapy also holds
great promise, but there might be a long way still to go.
Interference with autophagy or exocytosis has been
looming at the horizon for 50 years as a potential treat-
ment for lysosomal storage disorders. This subject was
rejuvenated, and present day insight offers an exciting
window of yet unknown opportunities.
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